Helene A. Yuen

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

A. Stopeck, J. Cherrington, J. Karp, 2004, Leukemia research.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

M. Heinrich, A. Town, T. Abrams, 2003, Blood.

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

M. Heinrich, J. Cherrington, R. Paquette, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.

J. Cherrington, F. Giles, M. Albitar, 2001, Blood.

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

H. Kantarjian, A. Stopeck, J. Cortes, 2003, Blood.

SU 11248 is a novel FLT 3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Cherrington, M. Heinrich, A. Town, 2003 .